Funding for this research was provided by:
Ruhr-Universität Bochum (Forum)
Received: 13 September 2018
Accepted: 25 February 2019
First Online: 9 March 2019
Ethics approval and consent to participate
: All experiments were reviewed and approved by the North-Rhine-Westphalia, Germany authorities for animal experimentation (TVA 84-02.04.2017-A023).
: Not applicable
: Kalliopi Pitarokoili received travel funding and speaker honoraria from Biogen Idec, Novartis and Bayer Schering Pharma and funding from the Ruhr-University, Bochum (FORUM-Program). Thomas Grüter received a travel reimbursement from Sanofi Genzyme and Biogen Idec, none related to this manuscript. Jeremias Motte received travel grants from Biogen Idec, none related to this work. Björn Ambrosius received travel grants from Novartis, not related to this manuscript. R. Gold has received consultation fees and speaker honoraria from Bayer Schering, Biogen idec, Merck Serono, Novartis, Sanofi-Aventis, and TEVA. He also acknowledges grant support from Bayer Schering, Biogen idec, Merck Serono, Sanofi-Aventis, and TEVA, none related to this manuscript. Min-Suk Yoon has received speaker honoraria from CSL Behring and Grifols, scientific grant from CSL Behring, none related to this manuscript. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.